Your browser doesn't support javascript.
The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge.
Murrieta-Álvarez, Iván; Cantero-Fortiz, Yahveth; León-Peña, Andrés A; Olivares-Gazca, Juan C; Priesca-Marín, José Manuel; Ruiz-Delgado, Guillermo J; Gómez-De-León, Andrés; Gonzalez-Lopez, Elías Eugenio; Jaime-Pérez, José Carlos; Gómez-Almaguer, David; Ruiz-Argüelles, Guillermo J.
  • Murrieta-Álvarez I; Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico.
  • Cantero-Fortiz Y; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico.
  • León-Peña AA; Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico.
  • Olivares-Gazca JC; Escuela de Medicina, Universidad de las Américas Puebla, Puebla, Mexico.
  • Priesca-Marín JM; Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico.
  • Ruiz-Delgado GJ; Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
  • Gómez-De-León A; Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico.
  • Gonzalez-Lopez EE; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico.
  • Jaime-Pérez JC; Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico.
  • Gómez-Almaguer D; Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico.
  • Ruiz-Argüelles GJ; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico.
Front Neurol ; 12: 647425, 2021.
Article in English | MEDLINE | ID: covidwho-1369681
ABSTRACT
After gaining experience conducting both auto and allografts in persons with hematological diseases in the HSCT programs in Puebla and Monterrey, México, this study outlines subsequent program autografting patients with autoimmune conditions. The first transplant in multiple sclerosis was conducted in Puebla on July 5, 2006. From 2015 we increased activity autografting persons with autoimmune conditions in the two campuses of the HSCT-México program Puebla and Monterrey. By December 6, 2020, patient number 1,000 in the program was autografted. In our experience, a significant reduction in the expanded disability status scale score was achieved in all of the three phenotypes of the disease (from a median of 5.1 to 4.5 points), whereas the response rate (defined as a decrease of at least 0.5 of EDSS score regardless of baseline EDSS, or unchanged EDSS) was 83, 78, and 73% after 12 months in the relapsing-remitting, primary-progressive and secondary-progressive forms of multiple sclerosis, respectively. In addition to analyzing the viability, safety, and efficacy of our method, this study contributes new knowledge to the field of both stem cell transplantation and multiple sclerosis.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Qualitative research Country/Region as subject: Mexico Language: English Journal: Front Neurol Year: 2021 Document Type: Article Affiliation country: Fneur.2021.647425

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Qualitative research Country/Region as subject: Mexico Language: English Journal: Front Neurol Year: 2021 Document Type: Article Affiliation country: Fneur.2021.647425